| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: Departments of1 Leukemia, 2 Bioimmunotherapy, and 3 Laboratory Medicine, the University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Jorge Cortes, Department of Leukemia, the University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030. Phone: 713-794-5783; Fax: 713-794-4297; E-mail: jcortes{at}mdanderson.org.
Purpose: To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib.
Experimental Design: We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic remission with imatinib (117 after IFN-
failure and 163 previously untreated). Median follow-up was 31 months (range, 3-52 months).
Results: Median BCR-ABL/ABL ratio before the start of therapy was 39.44 (range, 0.252-170.53). A major molecular response (BCR-ABL/ABL ratio <0.05%) was achieved in 174 (62%), and transcripts became undetectable (complete molecular response) in 95 (34%). By multivariate analysis, only treatment with high-dose imatinib (P = 0.02) was associated with achievement of a major molecular response. Nine of 166 (5%) patients who achieved a major molecular response lost their cytogenetic remission, compared with 25 of 68 (37%) among those who did not achieve this response (P < 0.0001). Patients achieving a major molecular response 12 months after the start of therapy had significantly better complete cytogenetic remission duration than others. A >1-log reduction in transcript levels after 3 months of therapy predicted for an improved probability of achieving a major molecular response at 24 months. Increasing levels of BCR-ABL transcripts predicted for a loss of cytogenetic remission only among patients who did not achieve a major molecular response.
Conclusions: Achieving a major molecular response, particularly within the first year of therapy, is predictive of a durable cytogenetic remission and may be the future goal of therapy in CML.
Key Words: Imatinib • Molecular responses • Chronic myeloid leukemia • PCR • Leukemias and lymphomas
This article has been cited by other articles:
|
|
 |
|
  E. Jabbour, H. Kantarjian, D. Jones, M. Breeden, G. Garcia-Manero, S. O'Brien, F. Ravandi, G. Borthakur, and J. Cortes Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood, July 1, 2008; 112(1): 53 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I-U. Chen, H. T. Maecker, and P. P. Lee Development and dynamics of robust T-cell responses to CML under imatinib treatment Blood, June 1, 2008; 111(11): 5342 - 5349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF]
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment Blood, February 1, 2008; 111(3): 1039 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood, December 1, 2007; 110(12): 4005 - 4011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Palandri, I. Iacobucci, F. Quarantelli, F. Castagnetti, D. Cilloni, M. Baccarani, and on behalf of the GIMEMA Working Party on CML Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase Haematologica, November 1, 2007; 92(11): 1579 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase Blood, October 15, 2007; 110(8): 2991 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Muller, G. Saglio, F. Lin, H. Pfeifer, R. D. Press, R. R. Tubbs, P. Paschka, E. Gottardi, S. G. O'Brien, O. G. Ottmann, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR Haematologica, July 1, 2007; 92(7): 970 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, R. Pasquini, N. Hamerschlak, P. Rousselot, J. Holowiecki, S. Jootar, T. Robak, N. Khoroshko, T. Masszi, A. Skotnicki, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Blood, June 15, 2007; 109(12): 5143 - 5150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O'Brien, F. Giles, and M. Albitar Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia Haematologica, February 1, 2007; 92(2): 170 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, D. Jones, F. Giles, G. Garcia-Manero, S. Faderl, F. Ravandi, M. B. Rios, J. Shan, et al. Survival benefit with imatinib mesylate versus interferon-{alpha}-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Blood, September 15, 2006; 108(6): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, J. Cortes, H. M. Kantarjian, S. Giralt, D. Jones, R. Jones, F. Giles, B. S. Andersson, R. Champlin, and M. de Lima Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure Blood, August 15, 2006; 108(4): 1421 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakanishi, K. Shiozawa, B. A. Hassel, and D. D. Ross Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression Blood, July 15, 2006; 108(2): 678 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., June 15, 2006; 354(24): 2542 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Press, Z. Love, A. A. Tronnes, R. Yang, T. Tran, S. Mongoue-Tchokote, M. Mori, M. J. Mauro, M. W. Deininger, and B. J. Druker BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML Blood, June 1, 2006; 107(11): 4250 - 4256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iacobucci, G. Saglio, G. Rosti, N. Testoni, F. Pane, M. Amabile, A. Poerio, S. Soverini, S. Bassi, D. Cilloni, et al. Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3037 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Pardinas, L. Xiao, J. Zhang, and K. Li Re: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, March 1, 2006; 98(5): 362 - 363. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Iacobucci, G. Rosti, M. Amabile, A. Poerio, S. Soverini, D. Cilloni, N. Testoni, E. Abruzzese, E. Montefusco, E. Ottaviani, et al. Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment J. Clin. Oncol., January 20, 2006; 24(3): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, H. Kantarjian, S. O'Brien, M. B. Rios, L. Abruzzo, S. Verstovsek, G. Garcia-Manero, and J. Cortes Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate Blood, January 15, 2006; 107(2): 480 - 482. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
